Clínic Barcelona

IDIBAPS welcomes the third meeting of COST Action BM1206 for genetic studies of colorectal cancer

Colorectal cancer (CRC) is one of the most frequent neoplasms worldwide and an important cause of morbidity in the developed world. It is necessary to identify individuals with a medium-high CRC risk in order to develop adequate preventive measures. The identification of inherited genetic factors involved in CRC susceptibility can help to profile individual disease risk and may enable early screening and treatment monitoring. COST Action BM1206 leaded from IDIBAPS by Sergi Castellví-Bel includes nowadays 98 participants from 22 countries actively working on CRC genetics. This Action will permit to comprehensively understand the impact of inherited susceptibility to CRC and to describe the genetic landscape of this disease, providing a highly innovative and unconditional tool for personalized CRC medicine with a future application in early screening and treatment monitoring for this disease.